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Background: Myostatin (Mstn) is a key regulator of heart metabolism and cardiomyocyte growth interacting tightly
with insulin-like growth factor I (IGF-I) under physiological conditions. The pathological role of Mstn has also been
suggested since Mstn protein was shown to be upregulated in the myocardium of end-stage heart failure. However,
no data are available about the regulation of gene expression of Mstn and IGF-I in different regions of healthy or
pathologic human hearts, although they both might play a crucial role in the pathomechanism of heart failure.
Methods: In the present study, heart samples were collected from left ventricles, septum and right ventricles of
control healthy individuals as well as from failing hearts of dilated (DCM) or ischemic cardiomyopathic (ICM) patients.
A comprehensive qRT-PCR analysis of Mstn and IGF-I signaling was carried out by measuring expression of Mstn, its
receptor Activin receptor IIB (ActRIIB), IGF-I, IGF-I receptor (IGF-IR), and the negative regulator of Mstn miR-208,
respectively. Moreover, we combined the measured transcript levels and created complex parameters characterizing
either Mstn- or IGF-I signaling in the different regions of healthy or failing hearts.
Results: We have found that in healthy control hearts, the ratio of Mstn/IGF-I signaling was significantly higher in the
left ventricle/septum than in the right ventricle. Moreover, Mstn transcript levels were significantly upregulated in all
heart regions of DCM but not ICM patients. However, the ratio of Mstn/IGF-I signaling remained increased in the left
ventricle/septum compared to the right ventricle of DCM patients (similarly to the healthy hearts). In contrast, in ICM
hearts significant transcript changes were detected mainly in IGF-I signaling. In paralell with these results miR-208
showed mild upregulation in the left ventricle of both DCM and ICM hearts.
Conclusions: This is the first demonstration of a spatial asymmetry in the expression pattern of Mstn/IGF-I in healthy
hearts, which is likely to play a role in the different growth regulation of left vs. right ventricle. Moreover, we identified
Mstn as a massively regulated gene in DCM but not in ICM as part of possible compensatory mechanisms in the
failing heart.
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Myostatin (Mstn), the growth inhibitor of skeletal muscle
[1], was shown to be expressed in the heart tissue [2] with
controversial data about its role in myocardial physiology
and pathophysiology. Based on the analysis of constitutive
Mstn knockout mice, numerous studies have demonstrated* Correspondence: mendler.luca@med.u-szeged.hu
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unless otherwise stated.that Mstn inhibits cardiac growth and contractility and
induces fibrosis [3-6]. Nevertheless, by analyzing adult
cardiac-specific Mstn mutants we have revealed recently a
beneficial role of Mstn in maintaining cardiac energy
homeostasis and preventing pathological cardiac hyper-
trophy [7].
Insulin-like growth factor I (IGF-I), on the other hand
was shown to play a pivotal role in cardiovascular physi-
ology and aging [8-10]. In concert with insulin itself, IGF-I
proved to be a positive regulator of cardiac growth and
contractility under both physiological and pathological
conditions [11-17]. Previous in vitro studies described ahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proposed that Mstn might be a cardiac chalone of IGF-I
since cardiac growth induced by IGF-I was feed-backed by
the overexpression of the negative growth regulator Mstn
[21]. However, no studies have systematically analyzed the
relevance of their possible reciprocal regulation at the
gene expression level in healthy or failing human hearts.
Previous investigations focused only on Mstn protein
activation that has been shown to be accelerated in hearts
of dilated or ischemic cardiomyopathic patients (DCM or
ICM, respectively) [22]. Moreover, no data exist in the
literature about the expression pattern of Mstn in com-
parison with IGF-I and their receptors in various regions
(i. e. left ventricles (LV) versus right ventricles (RV)) of the
human heart. Given the different functional requirements
LV and RV should cope with, and the markedly different
development of these regions, one could assume that the
gene expression pattern of Mstn and IGF-I signaling
might show remarkable spatial differences under both
physiological and pathological conditions. In the present
qRT-PCR study we report that Mstn/IGF-I signaling
differs in LV versus RV even in healthy hearts and shows
significant differences in DCM versus ICM patients.
Methods
Study design
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975. Informed consent was
obtained from all patients for being included in the study
according to the protocol approved by the Local Ethics
Committee (IK-NP-0021-24/1426/14). Healthy human
hearts were obtained from organ donor patients (CONT,
n = 5) whose hearts were explanted but due to technical
reasons (CMV infection, extensive damage during harvest
and size donor/recipient mismatch), not used for trans-
plantation. The donors did not present any important
previous medical history or any abnormalities in ECG
and echocardiography (LV dimensions/contractility within
normal ranges); these organ donors had died from head
trauma, cerebral or subarachnoid hemorrhage. Explanted
end-stage failing hearts were obtained from patients with
advanced heart failure of non-ischaemic (DCM) (n = 5) or
ischaemic aethiology (ICM) (n = 5). Before transplantation
the clinical state of all patients was determined according
to the New York Heart Association (NYHA) classifica-
tion; patients of NYHA class III–IV underwent a clinical
assessment that included resting electrocardiogram, echo-
cardiography and hemodynamic measurements.
Preparation of cardiac tissue
Tissue samples of the right and left ventricular free walls
and the inter-ventricular septum were taken at the timeof explantation (avoiding scarred, fibrotic, or adipose tissue,
endocardium, epicardium or coronary vessels). The samples
were rinsed immediately, blotted dry, frozen in liquid
nitrogen and kept at − 80°C until further processing.
qRT-PCR analysis of mRNA transcripts
Total RNA was isolated from the LV and RV as well as
from inter-ventricular septum (S) of the CONT, DCM or
ICM patients with the guanidinium thiocyanate-phenol-
chloroform method [23], followed by reverse transcription
(Sigma MMLV- Moloney Murine Leukemia Virus Reverse
Transcriptase, 28025-013). For the detection of the tran-
script levels of myostatin (Mstn), activin receptor IIB
(ActRIIB), insulin-like growth factor I (IGF-I) and insulin-
like growth factor I receptor (IGF-IR) quantitative PCR was
carried out with SYBR GREEN master mix (Fermentas) on
a Light Cycler 1.5 (Roche Applied Science). Since some of
the genes generally used for internal normalization in qRT-
PCR contain several pseudogenes (e.g. GAPDH, beta-actin)
of which co-amplification may compromise their reliability
as reference genes [24], hipoxanthine-guanine phosphory-
bosyltransferase (HPRT) has been used as a single internal
control gene in our experiments. Indeed, HPRT expression
did not significantly change between different groups or
heart regions (data not shown). Cycle conditions were set
as an initial denaturation step for 10 min at 95°C, followed
by 45 cycles of 10 sec at 95°C for template denaturation, 10
sec for annealing phase at 58°C and 10 sec at 72°C for
extension. Specificity of the PCR products was confirmed
by melting curve analysis followed by the verification of the
amplicon length on 1.5% agarose gels stained by ethidium
bromide. Primer pairs for Mstn, ActRIIB, IGF-I, IGF-IR
and HPRT were designed to intron spanning exons by
Primer 3 Input (version 0.4.0) software and tested to
avoid primer dimers, unspecific amplification and self-
priming formation (Table 1).
qRT-PCR analysis of miRNA transcripts
From the above detailed total RNA isolates, cDNA was
synthetized and quantitative real-time PCR was per-
formed with miRCURY LNA™ Universal RT microRNA
PCR kit (Exiqon, Denmark) on LightCycler®480 (Roche,
Switzerland) according to the manufacturer’s instructions.
Briefly, total RNA was diluted to a final concentration of 5
ng/μL, and mixed with Reaction buffer and Enzyme mix
provided with the kit in a final volume of 10 μL. Reaction
mixture was incubated for 60 min at 42°C, and reverse
transcriptase was heat-inactivated for 5 min at 95°C. Then,
cDNA was diluted to 80x and 4 μL of diluted cDNA were
mixed with 6 μL of the PCR Master mix and PCR primer
mix supplied by the manufacturer. The primers for both
microRNA-208b and microRNA-103a-3p was designed
and prepared by using Exiqon’s LNA™ technology. Poly-
merase was activated for 10 min at 95°C, and microRNA-
Table 2 Clinical, echocardiographic and hemodynamic
characteristics of DCM and ICM patients
CONT DCM ICM
Number of samples 5 5 5
Gender (female/male) 3/2 2/3 4/1
Age (year) 29 ± 9 39 ± 10 57 ± 11*#
NYHA functional class III/IV, n n.a. 0/5 3/2
PAP, mmHg n.a. 31.6 ± 4.7 30.8 ± 5.6
PWP, mmHg n.a. 24 ± 4.3 21 ± 3.5
LVED, mm n.a. 68 ± 4 71 ± 4
LVSD, mm n.a. 63 ± 5 61 ± 8
PW, mm n.a. 9.5 ± 0.5 10 ± 1.5
IVS, mm n.a. 10 ± 0.7 11 ± 1.5
LVEF, % n.a. 16 ± 3 23 ± 3
Medications
ACE-inhibitor - ++ ++
β-Blocker - ++ ++
Diuretics - ++ ++
Digitalis - + +
PDE-inhibitor - ++ ++
Dopamine/Noradrenaline ++ ++ +
Statin - - ++
Aspirin - - ++
Desmopressin ++ - -
Values are given in mean ± SEM; *p < 0.05 compared to control; #p < 0.05
compared to DCM Abbreviations: CONT: healthy control individuals, DCM: dilated
cardiomyopathy, ICM: ischemic cardiomyopathy, NYHA: New York Heart
Association, PAP: mean pulmonary artery pressure, PWP: mean pulmonary wedge
pressure, LVED: left ventricular end-diastolic diameter, LVSD: left ventricular
end-systolic diameter, PW: posterior wall thickness, IVS: interventricular septum
thickness, LVEF: left ventricular ejection fraction, ACE: angiotensin converting
enzyme, PDE: phosphodiesterase, n.a.: not applicable.
Table 1 Primer properties used in qRT-PCR
Target Accession number Forward primer Reverse primer Efficiency Product size (bp)
Mstn NM_005259.2 TTCGTCTGGAAACAGCTCCT CATTTGGGTTTTCCATCCAC 1.783 220
ActRIIB NM_001106.3 TGACTTTGGCTTGGCTGTTC ATGTACTCATCCACGGGTCC 1.834 219
IGF-I XM_005268835.1 ATGCTCTTCAGTTCGTGTGTG GGGTCTTGGGCATGTCGGTG 1.758 219
IGFI-R NM_000875.3 GACAACCAGAACTTGCAGCA GATTCTTCGACGTGGTGGTG 1.714 241
HPRT NM_000194.2 TGCTCGAGATGTGATGAAGG TCCCCTGTTGACTGGTCATT 2.044 192
bp: base pair, Mstn: myostatin, ActRIIB: activin receptor IIB, IGF-I: insulin-like growth factor I, IGFI-R: insulin-like growth factor I receptor, HPRT:
hypoxanthine-guanine phosphorybosyltransferase.
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fied (denaturation: 10 sec at 95°C; annealing/synthesis:
1 min at 60°C). The specificity of amplifications was
assessed by melting curve analysis (42°C to 80°C) and by
agarose gel electrophoresis (1%). At last, crossing point
values (Cp) were calculated. MicroRNA-208b Cp values
were normalized to the corresponding housekeeping
microRNA-103a-3p Cp values. Then, all pairwise ΔCp
value normalization was carried out to control ΔCp
values, and expressed as mean of the three replicated of
2-ΔΔCp values (fold change).
Definition of parameters characterizing Mstn and IGF-I
signaling in the heart
In order to describe the additive effect of Mstn and its
receptor ActRIIB transcript levels we combined these
data and defined a multiplied value of Mstn x ActRIIB as
‘Mstn signaling index’ for each analyzed sample. Similarly,
we created a multiplied value of IGF-I x IGF-IR transcript
levels referred to as ‘IGF-I signaling index’. To show the
ratio of Mstn and IGF-I signaling in the different regions
of healthy or failing hearts we divided the measured tran-
script levels by each other to produce either growth factor
ratio of Mstn/IGF-I or receptor ratio of ActRIIB/IGF-IR.
Finally, we created a complex parameter characterizing
the combined ratio of Mstn/IGF-I signaling by dividing
‘Mstn signaling index’ (Mstn x ActRIIB) by ‘IGF-I signal-
ing index’ (IGF-I x IGF-IR) referred to as ‘Mstn/IGF-I
signaling index’ ((Mstn x ActRIIB)/(IGF-I x IGF-IR)).
Statistical analysis
Statistical analysis was performed by one-way/two-way
ANOVA or non-parametric t-test (Welch test) using
Prism software (GraphPad Software, Inc.; San Diego, CA),
as appropriate. All data were expressed as means ± SEM.
For all analyses, a P value <0.05 was considered statisti-




A detailed summary of the pre-transplant data and drug
therapy of study subjects are shown in Table 2. Bothfemale and male patients were included in all groups.
The age of ICM patients differed as expected significantly
from both CONTand DCM, since ICM patients are usually
diagnosed with end-stage heart failure later than DCM pa-
tients. DCM and ICM patients were in either NYHA class
III or IV with no difference in pulmonary artery pressure
(PAP, PWP) left ventricle size parameters (LVED, LVSD,
IVS, PW) or left ventricular ejection fraction (LVEF) among
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treated) patients from the study to avoid possible modifica-
tion of the IGF-I signaling by insulin treatment. All patients
were managed with angiotensin-converting enzyme (ACE)-
inhibitors, beta-blockers and diuretics, however, aspirin
and statins were only used in case of ICM patients. CONT
subjects received iv. treatment composed of very low
catecholamine infusion (noradrenaline: 01.-0.2 μg/kg/min,
dopamine: 1-2 μg/kg/min) whereas adequate fluid balance
was maintained with intravenous fluids including colloids
(e.g. Voluven - hydroxyethyl starch) and Desmopressin.Figure 1 Gene expression levels of Mstn and IGF-I as well as their rec
left ventricles (LV) and right ventricles (RV) of control (CONT)-, DCM-,
ActRIIB- (B), IGF-I- (D), and IGF-IR- (E) transcript levels. Panel C shows ‘Mstn
F represents ‘IGF-I signaling index’ (IGF-I multiplied by IGF-IR mRNA levels). Da
(n = 5, *p < 0.05, **p < 0.01).Mstn and IGF-I signaling in healthy control hearts
So far, no comprehensive study has been carried out to
reveal gene expression of the growth regulators Mstn
and IGF-I and their receptors in different regions of
healthy human hearts. In the present work we detected
no significant difference in Mstn (Figure 1A) and ActRIIB
(Figure 1B) transcript levels nor in Mstn signaling index
(Figure 1C) between septum (S), left ventricle (LV) and
right ventricle (RV), however, Mstn levels showed decreas-
ing tendency in the RV (Figure 1A). In contrast, both
IGF-I mRNAs (Figure 1D) and IGF-I signaling indexeptors ActRIIB and IGF-IR normalized to HPRT in the septum (S),
and ICM hearts, respectively. Bars represent normalized Mstn- (A),
signaling index’ (Mstn multiplied by ActRIIB mRNA levels) while panel
ta are expressed in mean ± SEM, asterisks show significant differences
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panied with a significantly higher IGF-IR levels compared
to those of LV (Figure 1E). As a consequence, the ratio of
Mstn/IGF-I gene expression (Figure 2A) as well as those
of ActRIIB/IGF-I receptors (Figure 2B) and finally the
ratio of Mstn to IGF-I signaling (Figure 2C) all showed
significantly higher values in LV/S as compared to RV.
These data clearly demonstrate that Mstn signaling
dominates over IGF-I in the LV more than in RV of
healthy human hearts.
Mstn and IGF-I signaling in DCM patients compared to
healthy controls
In DCM patients we measured massive upregulation of
Mstn mRNA (Figure 1A) associated with an increased
Mstn signaling index (Figure 1C) in all heart regions
compared to CONT, although ActRIIB levels remained
relatively unchanged (Figure 1B). Similar to healthy hearts,
we found a significant upregulation of IGF-I transcripts
(Figure 1D) as well as of IGF-I signaling index (Figure 1F)
in RV of the failing hearts when compared to those of S,
although IGF-IR expression did not show significant
difference in either region nor in comparison to CONT
hearts (Figure 1E). Thus, the ratio of Mstn/IGF-I mRNAFigure 2 Growth factor ratio of Mstn/IGF-I (A), receptor ratio of ActRI
left ventricles (LV) and right ventricles (RV) of control (CONT)-, DCM-,
and IGF-I signaling referred to as ‘Mstn/IGF-I signaling index’ (‘Mstn signalin
IGF-IR)). Data are expressed in mean ± SEM, asterisks show significant differlevels (Figure 2A) and the Mstn/IGF-I signaling index
(Figure 2C) proved to be significantly higher in the left
versus right side of the DCM hearts and showed much
higher levels than those of the CONT regions. Since the
ratio of the ActRIIB/IGF-I receptors (Figure 2B) did not
change significantly we can conclude that Mstn was upreg-
ulated in all regions of failing hearts in DCM patients as
compared to CONT. However, given the higher IGF-I
levels in RV, left and right side of failing heart differed sig-
nificantly from each other in regard to the ratio of Mstn/
IGF-I signaling similar to those of healthy ones (Figure 2C).
Mstn and IGF-I signaling in ICM patients compared to
healthy controls
In contrast to DCM patients, we could not detect any
difference in either Mstn (Figure 1A) or ActRIIB transcript
levels (Figure 1B) or in Mstn signaling index (Figure 1C)
in any heart region of ICM patients compared to those of
CONT. Similarly, IGF-I (Figure 1D) and IGF-IR levels
(Figure 1E) as well as IGF-I signaling index (Figure 1F) did
not differ in ICM heart regions; however, in comparison
to CONT IGF-I showed a decreasing tendency of expres-
sion in the RV, while increased expression of IGF-IR in
the LV was present. Consequently, both ratios of Mstn/IB/IGF-IR (B) and ‘Mstn/IGF-I signaling index’ (C) in the septum (S),
and ICM hearts, respectively. Panel C represents the ratio of Mstn
g index’ divided by ‘IGF-I signaling index’ (Mstn x ActRIIB)/(IGF-I x
ences (n = 5, *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 3 Summary of gene expression alterations regarding
myostatin (Mstn) and IGF-I signaling in healthy human hearts
as well as in DCM and ICM patients, respectively. Bigger circles
represent higher expression of the signaling molecules in control vs.
DCM or ICM hearts or in left (left ventricle (LV) + septum (S)) vs. right
(right ventricle (RV)) side of the hearts.
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similar in all analyzed regions of ICM hearts. However,
significantly higher Mstn/IGF-I ratios were revealed in RV
due to decreased IGF-I levels as well as significantly lower
ActRIIB/IGF-IR ratios in LV when compared to CONT
hearts (due to increased IGF-IR levels). In summary, ICM
hearts did not show significantly altered modulation of
Mstn signaling in either heart region, whereas IGF-I sig-
naling, in contrast to the healthy situation, seemed to be
moderately induced in the LV, while inhibited in the RV.
Differences in Mstn/IGF-I signaling between DCM and
ICM patients
Based on our results, all regions of DCM hearts showed
significantly higher Mstn levels (Figure 1A) as well as
elevated Mstn signaling index (Figure 1C) than those of
ICM hearts. Moreover, ActRIIB (Figure 1B) also revealed
increased levels in LV of DCM vs. ICM patients. Never-
theless, we found no significant difference in IGF-I
signaling on the left side of failing hearts (Figure 1D-F),
although significantly less IGF-I transcripts were evident
on the right side of ICM hearts in comparison with that
of DCM ones (Figure 1D). As a consequence, all param-
eters describing the ratio of Mstn to IGF-I signaling
(Figure 2A-C) showed significantly increased values in
the LV of DCM versus ICM hearts. Although in the RV
we have revealed similar signaling ratio in both types of
failing hearts (Figure 2A-C) the reason for that was an
upregulation of Mstn signaling in DCM patients while a
downregulation of IGF-I signaling in ICM heart samples.
miR-208 expression in relation to Mstn expression in DCM
and ICM patients compared to healthy controls
In parallel with the massive upregulation of Mstn mRNA
in the left ventricle of DCM patients we measured a mild
upregulation of miR-208b (1.505 fold change) compared
to CONT. A similar but less pronounced upregulation
was seen in ICM hearts (1.405 fold change) when com-
pared to CONT, however, no significant difference was
detected between DCM and ICM patients.
Discussion
In the present comprehensive qRT-PCR study we have
found that Mstn dominated over IGF-I signaling much
more in the LV than in the RV of healthy human hearts,
and that DCM hearts upregulated Mstn expression in
contrast to ICM hearts. This is the first demonstration
that Mstn/IGF-I signaling differs in LV and RV in healthy
hearts and shows significant alterations in end-stage heart
failure due to DCM and ICM (Figure 3).
Several studies exist in the literature, indicating the
presence and/or de-regulation of both Mstn and IGF-I
under different conditions in the heart tissue, however,
the majority of data were collected from whole hearts orseparately from the LV [2,11,12,22]. Regarding Mstn
expression in healthy hearts, only one study has been
published so far on higher transcript levels of Mstn in
LV as compared to RV in young piglet hearts [25]. In line
with these data we have demonstrated here an obvious
reciprocal regulation of Mstn and IGF-I in LV compared
to RV characterized by elevated ratios of both Mstn/IGF-I
and ActRIIB/IGF-IR transcripts in healthy human LV
(Figure 3). Septum (S) samples, as being part of LV from
the functional point of view, revealed similar values to
those of LV in most cases. We assume that cardiomyocyte
growth in LV/S should be balanced more tightly by
growth inhibitors (i.e. Mstn) than that of RV since LV is
exposed to higher-pressure overload, while RV to a rela-
tively higher-volume overload. In addition to Mstn and
IGF-I, several other factors have been reported to be
enriched in either LV or RV; their asymmetric expression
might reflect a molecular predisposition of myocardium
to LV-concentric and RV-eccentric remodeling during
postnatal development [25,26]. Similarly, higher expres-
sion levels in LV vs. RV have been demonstrated for cyto-
chrome c oxidases and PGC1α, both of which are known
to contribute to maintain oxidative metabolism [27]. Re-
cently, we have also shown that Mstn plays an important
role in the regulation of oxidative metabolism of the myo-
cardium [7]. Therefore our results support the idea that
the elevated ratio of Mstn/IGF-I signaling is an important
regulatory mechanism under physiological conditions
maintaining higher workload and oxidative metabolism
in the LV.
In human failing hearts (in whole hearts or LV), Mstn
protein activation was reported to be accelerated in both
DCM and ICM patients [22]. In parallel with this obser-
vation several groups found increased serum levels of
Mstn protein in patients suffering from heart failure,
although no correlation was demonstrated with the
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also consider that elevated serum myostatin levels in
cardiomyopathic patients might be a combined effect of
increased secretion from both cardiac and skeletal muscles,
although exercise training lead to a reduction of myostatin
levels only in skeletal muscles but not in serum of patients
with chronic heart failure [31]. Nevertheless, it has been
not clarified, whether protein activation in failing heart is
regulated either at the level of gene expression or post-
transcriptionally. Here we show that DCM hearts are
indeed characterized by upregulated Mstn transcripts
in both LV/S and RV supporting the previous reports
on protein activation in LV [22]. However, we could not
detect any significant elevation of Mstn transcript levels
in ICM patients (Figure 3). We also tested the miRNA-
dependent posttranscriptional regulation of Mstn. MiR-
208 have been reported to be a negative regulator of Mstn
expression [32], and to be upregulated in various forms of
cardiomyopathy [33,34] and myocardial ischemia [35]. In
line with these we detected a mild upregulation of miR-
208b in the LV of DCM patients characterized by massive
increase of myostatin transcripts that might suggest an
adaptive counter regulatory mechanism fine-tuning the
expression of Mstn during heart failure. Since we have
found no difference in miR-208b expression between
DCM and ICM hearts, it is likely that higher levels of
myostatin mRNAs are mainly regulated at the level of
transcription.
Although alterations in Mstn gene expression are
followed by similar changes at the protein level in most
cases [36-38], the (extracellular) promyostatin-pool might
be posttranslationally activated by the cleavage of the
propeptide [39-41]. Thus, ICM patients might have a
Mstn activation at the protein level [22], however, not at
the level of gene expression, whereas DCM hearts react
with significant upregulation of Mstn transcripts. Similar
to the results of George et al. [22] we detected lower level
of ActRIIB in ICM than in DCM patients, but this
occured only in the LV. On the other hand, IGF-I expres-
sion was shown to be dynamically regulated in the course
of heart failure as an important compensatory mechanism;
however, conflicting data exist in the literature with both
down- and upregulated IGF-I levels in end-stage heart
failure [11,14,15]. We could confirm significant decrease
of IGF-I signaling in the RV of ICM patients but not in LV
or in DCM patients. Moreover, DCM patients still main-
tained the physiological difference in Mstn/IGF-I signaling
ratios in LV vs. RV, whereas no asymmetric gene expres-
sion pattern was detected in ICM patients (Figure 3). The
mechanisms leading to different regulation of growth
factor signaling in DCM and ICM patients remain to be
clarified, however, it might relate to the different pathome-
chanism of heart failure and/or alternative regulation of
compensatory mechanisms. Indeed, Mstn upregulationdetected in DCM hearts might be part of the compensa-
tion reactions since we have reported recently that acute
cardiac-specific deletion of Mstn in adult mouse hearts in-
duces dilated cardiomyopathy followed by a massive com-
pensatory up-regulation of Mstn in non-cardiomyocytes
[7]. It is known, however, that various cardiac disease
conditions, i.e. hypoxia can result in an imbalance of
chamber-associated gene expression in myocardium
[25-27,42]. Therefore, ICM hearts of ischemic origin
might not be able to compensate as effective as do DCM
patients by upregulating Mstn to maintain oxidative
metabolism [7] and by regulating their IGF-I signaling
to counter-act the decreased contractility [11]. However,
further research is needed to elucidate the physiological
and pathological relevance of the complex Mstn/IGF-I
network in human heart.Conclusions
Altogether, our results uncovered a spatial asymmetry in
the expression pattern of Mstn/IGF-I in healthy hearts,
which is likely to play a role in the different growth
regulation of LV vs. RV. Moreover, we identified Mstn as a
massively regulated gene in DCM but not in ICM as part
of possible compensatory mechanisms in the failing heart.Limitations
A clear limitation of the study is that our conclusions are
only based on transcript data. However, our goal was to
clarify transcriptional and posttranscriptional regulation of
myostatin/IGF-1 signaling which is missing from the lit-
erature and not the recapitulation of other studies mainly
concentrating on protein changes in heart failure patients
[22,28-30].
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